Wednesday, 20 January 2021

China NMPA approves CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy for thalassemia

China NMPA approves CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy for thalassemia admin Wed, 01/20/2021 - 16:05

source https://www.pharmatutor.org/pharma-news/2021/china-nmpa-approves-crispr-cas-9-gene-editing-hematopoietic-stem-cell-therapy-for-thalassemia
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...